LUCEMYRA
What it isCentral alpha-2 agonist; opioid withdrawal symptoms.
Why this oneIt is the only non-opioid agent approved for withdrawal, so it can be used where buprenorphine cannot.
What limits itHypotension, bradycardia and QT prolongation. It treats symptoms only and does nothing for craving or relapse.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Mitigation of opioid withdrawal symptoms | Adults | 0.54 mg (three 0.18 mg tablets) QID, 5–6 hr apart | guided by symptoms | 0.72 mg/dose; 2.88 mg/day; up to 14 days |
Renal eGFR 30–89.9: 0.36 mg (2 tabs) QID; <30 / ESRD / dialysis: 0.18 mg (1 tab) QID
Hepatic Mild: 0.54 mg (3 tabs) QID; moderate: 0.36 mg (2 tabs) QID; severe: 0.18 mg (1 tab) QID
Single dose ≤0.72 mg; total ≤2.88 mg/day; treat up to 14 days
Pregnancy Safety not established; animal harm (resorptions, litter loss, stillbirths) at exposures below human
Lactation No human data; exercise caution in nursing women
NO BOXED WARNINGS
Principal riskHypotension and QT prolongation; it does nothing for craving
Cost, est. cash$300–$2,500/month
Generic entry2032 est.
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Open Lofexidine in the interactive console ↗
